OOIR: Observatory of International Research

Papers

(The TQCC of Best Practice & Research Clinical Endocrinology & Metabolism is 15. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
Myeloma and marrow adiposity: Unanswered questions and future directions	102
The novel concept of “Onco-Immuno-Endocrinology” led to the discovery of new clinical entity “paraneoplastic autoimmune hypophysitis”	101
Editorial Board	68
Treatment of acromegaly with the nonpeptide, highly selective somatostatin receptor type 2 agonist paltusotine	65
Growth hormone replacement in adults with cured acromegaly: Efficacy and safety	52
Editorial Board	52
Editorial Board	51
Menopausal hormone therapy for the management of osteoporosis	50
Recent progress in molecular classification of phaeochromocytoma and paraganglioma	47
Genetics of pubertal timing	43
Regulation of bone mass: A splendid Orchestra	42
Coronavirus disease 2019 and vitamin D	40
Editorial Board	38
Polygenic risk scores for dyslipidemia and atherosclerotic cardiovascular disease: Progress toward clinical implementation	37
Rare forms of genetic steroidogenic defects affecting the gonads and adrenals	37
The role of androgens in transgender medicine	37
Sexual health and contraception in the menopause journey	36
Prenatal exposure to phthalate esters and its impact on child development	35
Editorial Board	34
Immune checkpoint inhibitor-related thyroid dysfunction	34
Remnant lipoprotein particles and cardiovascular disease risk	33
Optimal surgical approach for digestive neuroendocrine neoplasia primaries: Oncological benefits versus short and long-term complications	32
Cardiometabolic outcomes of early onset hypogonadism in males	31
Haematological actions of androgens	28
Molecular basis of symptomatic sporadic primary hyperparathyroidism: New frontiers in pathogenesis	27

Type 1 diabetes related to immune checkpoint inhibitors	27
Bone marrow adiposity and the hematopoietic niche: A historical perspective of reciprocity, heterogeneity, and lineage commitment	26
Endocrine-disrupting chemicals and behaviour: A high risk to take?	26
Acquired disorders of phosphaturia: Beyond tumor-induced osteomalacia	26
Epidemiology and risk factors for hypopituitarism due to traumatic brain injury	24
Radioiodine therapy in the different stages of differentiated thyroid cancer	24
Safety of long-term use of daily and long-acting growth hormone in growth hormone-deficient adults on cancer risk	24
Metabolic complications and their mechanisms in patients with craniopharyngioma	24
Medullary thyroid cancer - An update	24
Non-oestrogen-based and complementary therapies for menopause	23
Pathogenic role of Th17 cells in autoimmune thyroid disease and their underlying mechanisms	22
The effect of osteoporosis treatment on bone mass	22
Immune checkpoint inhibitor-related hypophysitis	21
Onco-immuno-endocrinology: An emerging concept that links tumor, autoimmunity, and endocrine disease	21
Approach to patients with elevated low-density lipoprotein cholesterol levels	21
Hormone therapy for menopause and premature ovarian insufficiency	21
Pathophysiology of thyroid-associated orbitopathy	21
Best Practice and Research Clinical Endocrinology and Metabolism focusing on Growth Hormone Deficiency in Adults – New Perspectives	20
Safety of androgen therapy in men with prostate cancer	20
Personalized management for phaeochromocytomas and paragangliomas in Latin America: A genetic perspective	20
Best practice and research clinical endocrinology and metabolism issue on phaeochromocytomas and paragangliomas	20
Editorial Board	20
Localization in primary hyperparathyroidism	19
The role of hormone therapy in urogenital health after menopause	19
Surgical outcomes in patients with acromegaly: Microscopic vs. endoscopic transsphenoidal surgery	19
History of androgens and androgen action	19
Recent advances in algorithms predicting hemodynamic instability undergoing surgery for phaeochromocytoma and paraganglioma	18
Editorial Board	18
Genotype-phenotype correlations in Graves’ disease	18
Post cancer care in women with an increased risk of malignancy or previous malignancy: The use of hormone replacement therapy and alternative treatments	18
Genetics of anti-Müllerian hormone and its signaling pathway	18
Editorial Board	18
Endocrine disrupting chemicals and bone	17
Preface	17
Best practice & research clinical endocrinology & metabolism focusing on the menopause – Diagnostic and therapeutic strategies	17
“Micromegaly”: Acromegaly with apparently normal GH, an entity on its own?	17
Exercise and physical activity in individuals at risk of fracture	16
Anaplastic thyroid cancer: An update	16
COVID-induced thyroid autoimmunity	16
Chemokines in thyroid autoimmunity	16
Editorial Board	15
Preclinical models for investigating how bone marrow adipocytes influence bone and hematopoietic cellularity	15
Preface	15
Paraneoplastic autoimmune hypophysitis: An emerging concept	15
The epidemiology of disorders of sex development	15